An influential presence in the Korean pharmaceutical sector, Celltrion accomplished what was deemed unattainable by introducing the world’s initial “antibody biosimilar” from a nation with a comparatively less advanced pharmaceutical industry. The corporation has spearheaded numerous unexplored domains to remarkable success, which it intends to pursue by furthering its expansion as a global biopharmaceutical company with distinctive strategies for small molecule pharmaceuticals and new ventures such as the Ubiquitous-healthcare platform business.
Products & Services
Infliximab Dyyb
Infliximab Stock CTH
Trastuzumab
Trastuzumab stock CTH
Sites
Celltrion
Country
South KoreaCelltrion healthcare united kingdom limited
City
Slough
Address
The switch 1-7 the grove, SL1 1QP